Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kineta ( (KANT) ) has provided an update.
Kineta, Inc. has entered into a merger agreement with TuHURA Biosciences, Inc., where TuHURA will acquire Kineta, including rights to its novel KVA12123 antibody. This merger is expected to enhance TuHURA’s pipeline with Kineta’s Phase 2 checkpoint inhibitor and create synergies with TuHURA’s existing technologies, potentially improving treatment outcomes for blood-related cancers. The transaction, subject to customary closing conditions, is anticipated to close in the first quarter of 2025.
More about Kineta
Kineta, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology, specifically addressing cancer immune resistance. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing technologies to overcome cancer immunotherapy resistance.
YTD Price Performance: -83.75%
Average Trading Volume: 51,482
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.24M
Learn more about KANT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue